![Akero Therapeutics, Inc. logo](/logos/AKRO.webp)
Akero Therapeutics, Inc.
NASDAQ:AKRO
Overview | Financials
Company Name | Akero Therapeutics, Inc. |
Symbol | AKRO |
Currency | USD |
Price | 26.41 |
Market Cap | 1,833,667,428 |
Dividend Yield | 0% |
52-week-range | 11.25 - 53.77 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Andrew Cheng M.D., Ph.D. |
Website | https://www.akerotx.com |
An error occurred while fetching data.
About Akero Therapeutics, Inc.
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD